FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W190502479> ?p ?o ?g. }

• W190502479 endingPage "1859" @default.
• W190502479 startingPage "1853" @default.
• W190502479 abstract "The present analysis reports on the pre-specified subgroup of ST-elevation myocardial infarction (STEMI) patients, in whom anticoagulant therapy has been of particular interest. In ATLAS ACS-2–TIMI-51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction-51), rivaroxaban reduced cardiovascular events across the spectrum of acute coronary syndrome (ACS). Seven thousand eight hundred seventeen patients in ATLAS ACS-2-TIMI 51 presented with a STEMI. After being stabilized (1 to 7 days), they underwent randomization to twice daily rivaroxaban 2.5 mg, rivaroxaban 5 mg, or placebo. Data are presented as 2-year Kaplan-Meier rates, and for intention-to-treat (ITT) and modified ITT (mITT) analyses. Among STEMI patients, rivaroxaban reduced the primary efficacy endpoint of cardiovascular death, myocardial infarction, or stroke, compared with placebo (ITT: 8.4% vs. 10.6%, hazards ratio [HR]: 0.81, 95% confidence interval [CI]: 0.67 to 0.97, p = 0.019; mITT: 8.3% vs. 9.7%, HR: 0.85, 95% CI: 0.70 to 1.03, p = 0.09). This reduction emerged by 30 days (ITT and mITT: 1.7% vs. 2.3%, p = 0.042) and was evident in analyses that included events while patients received background dual antiplatelet therapies (ITT: 7.9% vs. 11.9%, p = 0.010; mITT: 7.7% vs. 10.1%, p = 0.061). In terms of the individual doses, rivaroxaban 2.5 mg reduced cardiovascular death (ITT: 2.5% vs. 4.2%, p = 0.006; mITT: 2.2% vs. 3.9%, p = 0.006), which was not seen with 5 mg of rivaroxaban. Rivaroxaban versus placebo increased non-coronary artery bypass grafting Thrombolysis In Myocardial Infarction major bleeding (2.2% vs. 0.6%, p < 0.001) and intracranial hemorrhage (0.6% vs. 0.1%, p = 0.015) without a significant increase in fatal bleeding (0.2% vs. 0.1%, p = 0.51). In patients with a recent STEMI, rivaroxaban reduced cardiovascular events. This benefit emerged early and persisted during continued treatment with background antiplatelet therapies. Rivaroxaban compared with placebo increased the rate of major bleeding, but there was no significant increase in fatal bleeding. (An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome; NCT00809965)" @default.
• W190502479 created "2016-06-24" @default.
• W190502479 creator A5004104973 @default.
• W190502479 creator A5007026783 @default.
• W190502479 creator A5008461772 @default.
• W190502479 creator A5013502568 @default.
• W190502479 creator A5015803547 @default.
• W190502479 creator A5034203412 @default.
• W190502479 creator A5043533532 @default.
• W190502479 creator A5062053709 @default.
• W190502479 creator A5067186765 @default.
• W190502479 creator A5085897222 @default.
• W190502479 date "2013-05-01" @default.
• W190502479 modified "2023-10-04" @default.
• W190502479 title "Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction" @default.
• W190502479 cites W2072849188 @default.
• W190502479 cites W2084628164 @default.
• W190502479 cites W2085069921 @default.
• W190502479 cites W2110108344 @default.
• W190502479 cites W2117677020 @default.
• W190502479 cites W2123262447 @default.
• W190502479 cites W2168874562 @default.
• W190502479 doi "https://doi.org/10.1016/j.jacc.2013.01.066" @default.
• W190502479 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23500262" @default.
• W190502479 hasPublicationYear "2013" @default.
• W190502479 type Work @default.
• W190502479 sameAs 190502479 @default.
• W190502479 citedByCount "88" @default.
• W190502479 countsByYear W1905024792013 @default.
• W190502479 countsByYear W1905024792014 @default.
• W190502479 countsByYear W1905024792015 @default.
• W190502479 countsByYear W1905024792016 @default.
• W190502479 countsByYear W1905024792017 @default.
• W190502479 countsByYear W1905024792018 @default.
• W190502479 countsByYear W1905024792019 @default.
• W190502479 countsByYear W1905024792020 @default.
• W190502479 countsByYear W1905024792021 @default.
• W190502479 countsByYear W1905024792022 @default.
• W190502479 countsByYear W1905024792023 @default.
• W190502479 crossrefType "journal-article" @default.
• W190502479 hasAuthorship W190502479A5004104973 @default.
• W190502479 hasAuthorship W190502479A5007026783 @default.
• W190502479 hasAuthorship W190502479A5008461772 @default.
• W190502479 hasAuthorship W190502479A5013502568 @default.
• W190502479 hasAuthorship W190502479A5015803547 @default.
• W190502479 hasAuthorship W190502479A5034203412 @default.
• W190502479 hasAuthorship W190502479A5043533532 @default.
• W190502479 hasAuthorship W190502479A5062053709 @default.
• W190502479 hasAuthorship W190502479A5067186765 @default.
• W190502479 hasAuthorship W190502479A5085897222 @default.
• W190502479 hasBestOaLocation W1905024791 @default.
• W190502479 hasConcept C126322002 @default.
• W190502479 hasConcept C127413603 @default.
• W190502479 hasConcept C142724271 @default.
• W190502479 hasConcept C164705383 @default.
• W190502479 hasConcept C168563851 @default.
• W190502479 hasConcept C203092338 @default.
• W190502479 hasConcept C204787440 @default.
• W190502479 hasConcept C207103383 @default.
• W190502479 hasConcept C27081682 @default.
• W190502479 hasConcept C2776301958 @default.
• W190502479 hasConcept C2777698277 @default.
• W190502479 hasConcept C2777995511 @default.
• W190502479 hasConcept C2778661090 @default.
• W190502479 hasConcept C2779161974 @default.
• W190502479 hasConcept C2779581417 @default.
• W190502479 hasConcept C2780645631 @default.
• W190502479 hasConcept C44249647 @default.
• W190502479 hasConcept C500558357 @default.
• W190502479 hasConcept C71924100 @default.
• W190502479 hasConcept C78519656 @default.
• W190502479 hasConceptScore W190502479C126322002 @default.
• W190502479 hasConceptScore W190502479C127413603 @default.
• W190502479 hasConceptScore W190502479C142724271 @default.
• W190502479 hasConceptScore W190502479C164705383 @default.
• W190502479 hasConceptScore W190502479C168563851 @default.
• W190502479 hasConceptScore W190502479C203092338 @default.
• W190502479 hasConceptScore W190502479C204787440 @default.
• W190502479 hasConceptScore W190502479C207103383 @default.
• W190502479 hasConceptScore W190502479C27081682 @default.
• W190502479 hasConceptScore W190502479C2776301958 @default.
• W190502479 hasConceptScore W190502479C2777698277 @default.
• W190502479 hasConceptScore W190502479C2777995511 @default.
• W190502479 hasConceptScore W190502479C2778661090 @default.
• W190502479 hasConceptScore W190502479C2779161974 @default.
• W190502479 hasConceptScore W190502479C2779581417 @default.
• W190502479 hasConceptScore W190502479C2780645631 @default.
• W190502479 hasConceptScore W190502479C44249647 @default.
• W190502479 hasConceptScore W190502479C500558357 @default.
• W190502479 hasConceptScore W190502479C71924100 @default.
• W190502479 hasConceptScore W190502479C78519656 @default.
• W190502479 hasFunder F4320307105 @default.
• W190502479 hasFunder F4320307765 @default.
• W190502479 hasFunder F4320307773 @default.
• W190502479 hasFunder F4320307779 @default.
• W190502479 hasFunder F4320307781 @default.
• W190502479 hasFunder F4320320303 @default.
• W190502479 hasFunder F4320321625 @default.

• next